JHS Svendgaard Labs Q3 FY26: Net Profit ₹0.79 Lakhs (Standalone)
JHS Svendgaard Laboratories reported standalone net profit of ₹0.79 lakh for Q3 FY26, a turnaround from a loss last year. Consolidated net profit was ₹78.89 lakh. Revenue from operations stood at ₹23.85 crore (consolidated). The company also approved conversion of warrants into equity shares.
The financial results show a positive trend with a move from net loss to net profit, which is material for investors. The conversion of warrants also impacts the capital structure.
The company has shown a significant turnaround from losses to profits on both standalone and consolidated bases for the quarter and nine months ended December 31st, 2025, indicating improved financial performance.
JHS Svendgaard Laboratories Limited announced its un-audited standalone and consolidated financial results for the quarter and nine months ended December 31st, 2025, following a Board Meeting held on February 10th, 2026. The meeting commenced at 03:40 P.M. and concluded at 03:48 P.M.
For the standalone results, the company reported a net profit of ₹0.79 lakhs for the quarter ended December 31st, 2025. This compares to a loss of ₹15.51 lakhs in the same quarter of the previous year. Revenue from operations stood at ₹28.18 crore for the quarter. For the nine months ended December 31st, 2025, the standalone net profit was ₹56.02 lakhs, a significant improvement from a loss of ₹197.84 lakhs in the prior year period.
On a consolidated basis, the company reported a net profit of ₹78.89 lakhs for the quarter ended December 31st, 2025, compared to a loss of ₹183.66 lakhs in the corresponding quarter of the previous year. Consolidated revenue from operations for the quarter was ₹23.85 crore. For the nine months ended December 31st, 2025, the consolidated net profit was ₹164.63 lakhs, a turnaround from a loss of ₹1,278.51 lakhs in the same period last year.
The company also noted that out of the equity shares and warrants allotted on preferential basis on August 3rd, 2024, 18,01,801 warrants were converted into equity shares on February 1st, 2026. Remaining warrants lapsed due to non-conversion. The company has utilized funds from these issuances for project in Jammu and Kashmir, general corporate purposes, investment in JHS Svendgaard Retail Ventures Limited, and capital expenditure, with a portion parked in fixed deposits.
What to do with a filing like this
JHS Svendgaard Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by JHS Svendgaard Laboratories Limited. Read the original for the full detail.